Author:
Peng Ye,She Zhihua,Peng Liubao,Liu Qiao,Yi Lidan,Luo Xia,Li Sini,Wang Liting,Qin Shuxia,Wan Xiaomin,Tan Chongqing
Funder
National Natural Science Foundation of China
Key Science-Technology Research and Development Program of Hunan Province
Hunan Provincial Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference23 articles.
1. National Institutes of Health; National Cancer Institute; Surveillance, Epidemiology, and End Results Program. Cancer stat facts: bladder cancer. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed 14 Apr 2021.
2. Criss SD, Weaver DT, Sheehan DF, et al. Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States. Urol Oncol. 2019;37(3):180e111–8.
3. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
4. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: bladder cancer, version 2. 2021. https://www.nccn.org/professionals/physician_gls/PDF/bladder.pdf. Accessed 10 July 2021.
5. Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383(13):1218–30.